How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/unresectable-malignant-melanoma-with-braf-gene-mutation.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Unresectable malignant melanoma with BRAF gene mutation — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Unresectable malignant melanoma with BRAF gene mutation (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Unresectable malignant melanoma with BRAF gene mutation, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Target	First approval
Mektovi	mek162	Pfizer	Dual specificity mitogen-activated protein kinase kinase 1	2018-01-01
Braftovi	encorafenib	Pfizer	RAF proto-oncogene serine/threonine-protein kinase	2018-01-01
Mektovi	binimetinib	Pfizer	Dual specificity mitogen-activated protein kinase kinase 1	2018-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer · 3 drugs in Unresectable malignant melanoma with BRAF gene mutation

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Unresectable malignant melanoma with BRAF gene mutation:

Cite this brief

Drug Landscape (2026). Unresectable malignant melanoma with BRAF gene mutation — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/unresectable-malignant-melanoma-with-braf-gene-mutation. Accessed 2026-06-10.

Unresectable malignant melanoma with BRAF gene mutation full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing